[Ribo Newsroom] Ribo Secures Series E Funding to Accelerate Global siRNA Therapeutics Strategy

[Ribo Newsroom] Ribo's International R&D Center Ribocure Closes USD 33 Million Equity Financing to Accelerate Innovative siRNA Drug Development

[Our Products News] Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in Australia

[Our Products News] First Milestone Successfully Achieved in Ribo���s Collaboration in Liver Diseases With Boehringer Ingelheim

[Ribo Newsroom] Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics

[Our Products News] Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024

[Our Products News] Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA

[Our Products News] Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases